Molecular Signatures of Cutaneous Dupilumab Response (NCT05858619)

🧪 Interventions in This Study

• Dupilumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• University of California, San Francisco — San Francisco, California

📞 Contact the Study Coordinator

Phone: (415) 575-0524

Email: rashes@ucsf.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Atopic Dermatitis

• A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden — Birmingham, Alabama
• ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis — Phoenix, Arizona
• A Study of Barzolvolimab in Patients With Atopic Dermatitis — Birmingham, Alabama
• Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis — Chicago, Illinois
• A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis — Birmingham, Alabama
• A Study Evaluating APG777 in Atopic Dermatitis — Fountain Valley, California

Explore by condition: All Atopic Dermatitis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.